Source: International Congress 2014 – Asthma and COPD devices and treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Chrystyn, S. Pascual, J. Feimer, A. De Soyza, J. Sauleda Roig, J. Haughney, L. Padullés, B. Seoane, L. Rekeda, A. Ribera (Huddersfield, Newcastle upon Tyne, Glasgow, United Kingdom; Barcelona, Palma de Mallorca, Spain; Munich, Germany; , United States Of America). Preference, satisfaction and critical errors with Genuair^® and Breezhaler^® in patients with COPD. Eur Respir J 2014; 44: Suppl. 58, 928

Member's Comments

No comment yet.

Related content which might interest you: Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat® Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Predictors of good inhaler technique in asthma and COPD Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 LATE-BREAKING ABSTRACT: Outcome of withdrawal of one inhaler in COPD patients received combined ICS/LABA and LAMA Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Comparison of asthma and COPD patients' perception of appropriate metered-dose inhaler technique with a questionnaire and supervision based reference standard Source: International Congress 2014 – Clinical assessment of airway diseases Year: 2014 Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Do correct steps using pMDI technique with spacer predict no exacerbations of Asthma or COPD? Source: International Congress 2016 – Asthma and allergy in infancy: from risk factors to mortality Year: 2016 Inhaler competence and patient satisfaction with a DPI; results of two real-life studies in asthma and COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Bronchodilators delivered by nebuliser versus pMDI for exacerbations of COPD - A Cochrane review Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Is therapy adherence with inhaled tiotropium in COPD related to hospitalization, pneumonia or mortality? Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Differences in adherence to common inhaled medications in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013